NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market
The $3.29 share purchase price represents a 20% premium to the November 6, 2026 closing price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NewcelX (Nasdaq: NCEL) entered into securities purchase agreements for a private placement priced to raise $1.55 million for its development activities.
The financing comprises 471,125 common shares at $3.29 each, a 20% premium to the November 6, 2026 closing price, and warrants to purchase 353,344 shares at $3.75 each. Closing is expected on or about November 23, 2026, subject to customary closing conditions. International healthcare investors and The Crushing T1 Foundation are participating, alongside existing shareholders.
The company plans to use net proceeds, current cash and its previously announced $25 million equity line to advance NCEL-101 for type 1 diabetes with Eledon Pharmaceuticals. Planned work includes an FDA-required toxicology study needed before human testing, manufacturing development and preparations for a Phase 1/2a trial in 2027, alongside working capital and general corporate purposes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.$1.55 million private placement under signed purchase agreements provides expected funding for development activities. 9.8% of market cap
- Minor point$3.29 share price represents a 20% premium to the November 6, 2026 closing price.
- Minor point. Forward-looking: it has not happened yet and may not happen.NCEL-101 toxicology study required by the FDA is a planned use of financing proceeds.
- Minor point. Forward-looking: it has not happened yet and may not happen.Cell manufacturing capabilities are slated for advancement using proceeds alongside existing funding sources.
- Minor point. Forward-looking: it has not happened yet and may not happen.Phase 1/2a trial in 2027 is planned, with financing intended to support preparations.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.471,125 common shares at $3.29 each will dilute existing shareholders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Warrants for 353,344 shares at $3.75 each create potential additional dilution.
News Explained
U.S. resale of the unregistered securities is restricted unless they are registered or an applicable exemption applies.
NewcelX has entered into purchase agreements for a private placement, with closing expected on or about
The securities are unregistered and may not be offered or sold in the United States unless covered by an effective registration statement or an applicable exemption.
Key Figures
- Financing size
- $1.55 million
- Private placement
- Purchase price
- $3.29 per share
- Private placement
- Premium to last close
- 20%
- Based on the November 6, 2026 closing price
- Common shares offered
- 471,125 shares
- Private placement
- Warrants
- 353,344 common shares
- Shares purchasable under the warrants
- Warrant exercise price
- $3.75 per share (137% of the November 6 close)
- Warrants issued with the placement
- Expected closing
- On or about November 23, 2026
- Subject to customary closing conditions
- Planned trial timing
- 2027
- Planned Phase 1/2a clinical trial for NCEL-101
Historical Context
-
Priced a $1.4 million placement at a 20% premium, with shares and warrants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
warrants financial
regulation d regulatory
pre-ind regulatory
ind-enabling toxicology study medical
human pluripotent stem cell medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The financing led by international healthcare investors, alongside The Crushing T1 Foundation, reinforces confidence in NewcelX’s strategy and long-term potential
ZURICH, Nov. 09, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of
Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 471,125 common shares and one series of warrants to purchase an aggregate of 353,344 common shares at an exercise price of
The offering includes participation from existing shareholders and is expected to close on or about November 23, 2026, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering, together with its current cash position, and previously announced
“We are pleased to welcome this distinguished group of healthcare investors, whose experience, reputation, and long-term perspective bring significant value beyond their financial investment,” said Ronen Twito, CEO & Executive Chairman of NewcelX. “We believe that their participation, together with involvement of The Crushing T1 Foundation, represents a strong vote of confidence in our technology, strategy, and clinical potential. Importantly, the investment at a substantial premium to the prevailing market price underscores the conviction of these investors in the long-term value of NewcelX. This financing comes at an important stage as we advance toward initiating our IND-enabling studies following our successful Pre-IND meeting with the FDA and prepare for our planned Phase 1/2a clinical trial in 2027, in collaboration with Eledon Pharmaceuticals.”
The securities described above are being issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About NewcelX
NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.
Social Media: LinkedIn, Facebook, X, Instagram
Website: www.newcelx.com
Forward-Looking Statements
This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds therefrom, the advancement and development of NCEL-101, the initiation and timing of IND-enabling studies, its manufacturing capabilities and scalability, and the timing and commencement of its planned Phase 1/2a clinical trial, including its plans to commence such trial in 2027. These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the regulatory pathways that NewcelX may elect to utilize in seeking European Medicines Agency, the FDA, and other regulatory approvals; its ability to drive revenue growth, enhance research and development capabilities, and improve financial performance is subject to uncertainties; that its financial position raises substantial doubt about its ability to continue as a going concern; its ability to maintain listing and effectively comply with the listing requirements of the Nasdaq; changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials, including its expectations regarding the timing of commencing further clinical trials, the process entailed in conducting each such trial, including dosages, and the order of such trials with each of its product candidates or whether such trials will be conducted at all; competitive companies, technologies and its industry; the development and commercialization, if any, of any other product candidates that it may seek to develop; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; the scope of protection it is able to establish and maintain for intellectual property rights covering its product candidates and its ability to operate its business without infringing the intellectual property rights of others; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; its ability to establish and maintain strategic partnerships and other corporate collaborations; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; delays in developing or introducing new technologies, products, or applications; competitive pressures that could reduce market share or pricing; the overall global political and economic environment in the countries in which we operate; and security, political and economic instability in the Middle East that could harm its business, including due to the current security situation in Israel. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission ("SEC") and available at www.sec.gov, as well as in subsequent filings made by NewcelX.
Investor Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
NewCelX@kcsa.com
Company Contact
Sarah Bazak
InvestorRelations@newcelx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of NewcelX's $1.55 million private placement?
NewcelX is selling 471,125 common shares at $3.29 each and warrants to purchase 353,344 common shares at $3.75 each. The share purchase price is a 20% premium to the November 6, 2026 closing price; the warrant exercise price is 137% of that closing price.
When is NewcelX's private placement expected to close?
The private placement is expected to close on or about November 23, 2026, subject to satisfaction of customary closing conditions.